Association of Long-Term 5α-Reductase Inhibitor Use With Survival in Men With Renal Cell Carcinoma: A Nationwide Population-Based Cohort Study
May 2026
in “
Frontiers in Pharmacology
”
Studysummary This study found that long-term use of 5α-reductase inhibitors is associated with improved overall survival in men with renal cell carcinoma, particularly those with low comorbidity not receiving surgery or systemic therapy, suggesting a potential role for androgen modulation in disease management.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on frontiersin.org →